Date: 2014-07-02
Type of information: Licensing agreement
Compound: conditional knockout (KO) models
Company: genOway (France), the Wellcome Trust Sanger Institute (UK), Helmholtz Zentrum Muenchen (Germany), members of the EUCOMM Program (European Conditional Mouse Mutagenesis Program) and its successor program EUCOMMTOOLS
Therapeutic area: Technology - Services
Type agreement: licensing
Action mechanism: The EUCOMM project was funded by the European Union Sixth Framework Program and its successor EUCOMMTOOLS by the Seventh Framework Program. It will generate, distribute and archive up to 11,500 conditional, targeted KO mouse models with mutations across the mouse genome. This forms part of the International Knockout Mouse Consortium (IKMC) effort. Making these valuable materials available to the research community is core to the EUCOMM and EUCOMMTOOLS projects.
Disease:
Details: * On July 2, 2014, genOway, a French biotechnology company dedicated to the development of genetically modified animal models, the Wellcome Trust Sanger Institute (UK) and Helmholtz Zentrum Muenchen (Germany), members of the EUCOMM Program (European Conditional Mouse Mutagenesis Program) and its successor program EUCOMMTOOLS (EUCOMM: Tools for functional annotation of the mouse genome) have announced the signing of a license enabling genOway to provide industry scientists with conditional knockout (KO) models developed by EUCOMM. EUCOMM/EUCOMMTOOLS provide access to their growing conditional KO repository with 9,500 models. genOway provides the necessary intellectual property rights to use these models, including the IRES or Homologous Recombination exclusive technologies. The agreement enables short timespans to access EUCOMM/EUCOMMTOOLS materials and generate conditional KO models from them.
Financial terms: Financial terms were not disclosed.
Latest news:
